设为首页 加入收藏

TOP

(paliperidone palmitate extended-release injectable suspension)
2016-09-10 09:23:52 来源: 作者: 【 】 浏览:344次 评论:0
  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use INVEGA TRINZA ® safely and effectively. See full prescribing information for INVEGA TRINZA ®.
    INVEGA TRINZA ® (paliperidone palmitate) extended-release injectable suspension, for intramuscular use
    Initial U.S. Approval: 2006
    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS
    See full prescribing information for complete boxed warning.
    • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. (5.1)
    • INVEGA TRINZA® is not approved for use in patients with dementia-related psychosis. (5.1)
    INDICATIONS AND USAGE

    INVEGA TRINZA®, a 3-month injection, is an atypical antipsychotic indicated for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension) for at least four months. (1)
    DOSAGE AND ADMINISTRATION

    • Use INVEGA TRINZA® only after the patient has been adequately treated with the 1-month paliperidone palmitate extended-release injectable suspension for at least four months. (2.2)
    • INVEGA TRINZA® should be administered once every 3 months. (2.1)
    • For intramuscular injection only. (2.1)
    • Each injection must be administered only by a health care professional. (2.1)
    • For deltoid injection: For patients weighing less than 90 kg, use the 1-inch 22 gauge thin wall needle. For patients weighing 90 kg or more, use the 1½-inch 22 gauge thin wall needle.
    • For gluteal injection: Regardless of patient weight, use the1½-inch 22 gauge thin wall needle.
    • Prior to administration, shake the prefilled syringe vigorously for at least 15 seconds within 5 minutes prior to administration to ensure a homogeneous suspension. (2.1)
    • Initiate INVEGA TRINZA® when the next 1-month paliperidone palmitate dose is scheduled with an INVEGA TRINZA® dose based on the previous 1-month injection dose as shown below. (2.2)
    INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®
    If the Last Dose of INVEGA SUSTENNA® is: Initiate INVEGA TRINZA® at the Following Dose:
    Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
    78 mg 273 mg
    117 mg 410 mg
    156 mg 546 mg
    234 mg 819 mg
    • Missed Doses: Missing doses of INVEGA TRINZA® should be avoided. To manage missed doses on exceptional occasions, refer to the Full Prescribing Information. (2.3)
    • Moderate to severe renal impairment (creatinine clearance < 50 mL/min): INVEGA TRINZA® is not recommended. (2.5)
    • Mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min): Adjust dosage and stabilize the patient using INVEGA SUSTENNA®, then transition to INVEGA TRINZA®. See above table. (2.5)
    DOSAGE FORMS AND STRENGTHS

    Extended-release injectable suspension: 273 mg, 410 mg, 546 mg, or 819 mg (3)
    CONTRAINDICATIONS
    Known hypersensitivity to paliperidone, risperidone, or to any excipients in INVEGA TRINZA®. (4)
    WARNINGS AND PRECAUTIONS

    • Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis: Increased incidence of cerebrovascular adverse reactions (e.g. stroke, transient ischemic attack, including fatalities). INVEGA TRINZA® is not approved for use in patients with dementia-related psychosis (5.2)
    • Neuroleptic Malignant Syndrome: Manage with immediate discontinuation of drug and close monitoring (5.3)
    • QT Prolongation: Avoid use with drugs that also increase QT interval and in patients with risk factors for prolonged QT interval (5.4)
    • Tardive Dyskinesia: Discontinue drug if clinically appropriate (5.5)
    • Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include:
      • Hyperglycemia and Diabetes Mellitus: Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness. Monitor glucose regularly in patients with diabetes or at risk for diabetes. (5.6)
      • Dyslipidemia: Undesirable alterations have been observed. (5.6)
      • Weight Gain: Significant weight gain has been reported. Monitor weight gain. (5.6)
    • Orthostatic Hypotension and Syncope: Use with caution in patients with known cardiovascular or cerebrovascular disease and patients predisposed to hypotension (5.7)
    • Leukopenia, Neutropenia, and Agranulocytosis: Monitor complete blood count in patients with a history of a clinically significant low white blood cell count (WBC) or a drug-induced leukopenia/neutropenia. Consider discontinuation if clinically significant decline in WBC in the absence of other causative factors (5.8)
    • Hyperprolactinemia: Prolactin elevations occur and persist during chronic administration (5.9)
    • Potential for Cognitive and Motor Impairment: Use caution when operating machinery (5.10)
    • Seizures: Use cautiously in patients with a history of seizures or with conditions that lower the seizure threshold (5.11)
    ADVERSE REACTIONS

    The most common adverse reactions (incidence ≥ 5% and occurring at least twice as often as placebo) were injection site reaction, weight increased, headache, upper respiratory tract infection, akathisia, and parkinsonism. (6)

    To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

    DRUG INTERACTIONS

    Strong CYP3A4/P-glycoprotein (P-gp) inducers: Avoid using a strong inducer of CYP3A4 and/or P-gp (e.g., carbamazepine, rifampin, St John's Wort) during a dosing interval for INVEGA TRINZA®. If administering a strong inducer is necessary, consider managing the patient using paliperidone extended release tablets. (7.2, 12.3)

    USE IN SPECIFIC POPULATIONS

    Pregnancy: May cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure. (8.1)

    See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

    Revised: 3/2016

  • FULL PRESCRIBING INFORMATION: CONTENTS*

    WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

    1 INDICATIONS AND USAGE

    2 DOSAGE AND ADMINISTRATION

    2.1 Administration Instructions

    2.2 Schizophrenia

    2.3 Missed Doses

    2.4 Use with Risperidone or with Oral Paliperidone

    2.5 Dosage Adjustment in Renal Impairment

    2.6 Switching from INVEGA TRINZA® to the 1-Month Paliperidone Palmitate Extended-Release Injectable Suspension

    2.7 Switching from INVEGA TRINZA® to Oral Paliperidone Extended-Release Tablets

    2.8 Instructions for Use

    3 DOSAGE FORMS AND STRENGTHS

    4 CONTRAINDICATIONS

    5 WARNINGS AND PRECAUTIONS

    5.1 Increased Mortality in Elderly Patients with Dementia-Related Psychosis

    5.2 Cerebrovascular Adverse Reactions, Including Stroke, in Elderly Patients with Dementia-Related Psychosis

    5.3 Neuroleptic Malignant Syndrome

    5.4 QT Prolongation

    5.5 Tardive Dyskinesia

    5.6 Metabolic Changes

    5.7 Orthostatic Hypotension and Syncope

    5.8 Leukopenia, Neutropenia, and Agranulocytosis

    5.9 Hyperprolactinemia

    5.10 Potential for Cognitive and Motor Impairment

    5.11 Seizures

    5.12 Dysphagia

    5.13 Priapism

    5.14 Disruption of Body Temperature Regulation

    6 ADVERSE REACTIONS

    6.1 Clinical Trials Experience

    6.2 Postmarketing Experience

    7 DRUG INTERACTIONS

    7.1 Drugs Having Clinically Important Interactions with INVEGA TRINZA®

    7.2 Drugs Having No Clinically Important Interactions with INVEGA TRINZA®

    8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    8.2 Lactation

    8.4 Pediatric Use

    8.5 Geriatric Use

    8.6 Renal Impairment

    8.7 Hepatic Impairment

    8.8 Patients with Parkinson's Disease or Lewy Body Dementia

    9 DRUG ABUSE AND DEPENDENCE

    9.1 Controlled Substance

    9.2 Abuse

    9.3 Dependence

    10 OVERDOSAGE

    10.1 Human Experience

    10.2 Management of Overdosage

    11 DESCRIPTION

    12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    12.2 Pharmacodynamics

    12.3 Pharmacokinetics

    13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    13.2 Animal Toxicology and/or Pharmacology

    14 CLINICAL STUDIES

    16 HOW SUPPLIED/STORAGE AND HANDLING

    17 PATIENT COUNSELING INFORMATION

    *
    Sections or subsections omitted from the full prescribing information are not listed.
  • 1 INDICATIONS AND USAGE

     NVEGA TRINZA® (paliperidone palmitate), a 3-month injection, is indicated for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension) for at least four months [see Dosage and Administration (2.2) and Clinical Studies (14)].

  • 2 DOSAGE AND ADMINISTRATION

     

    2.1 Administration Instructions

    INVEGA TRINZA® should be administered once every 3 months.

    Each injection must be administered only by a health care professional.

    Parenteral drug products should be inspected visually for foreign matter and discoloration prior to administration. It is important to shake the syringe vigorously for at least 15 seconds to ensure a homogeneous suspension. Inject INVEGA TRINZA® within 5 minutes of shaking vigorously [see Dosage and Administration (2.8)].

    INVEGA TRINZA® is intended for intramuscular use only. Do not administer by any other route. Avoid inadvertent injection into a blood vessel. Administer the dose in a single injection; do not administer the dose in divided injections. Inject slowly, deep into the deltoid or gluteal muscle.

    INVEGA TRINZA® must be administered using only the thin wall needles that are provided in the INVEGA TRINZA® pack. Do not use needles from the 1-month paliperidone palmitate extended-release injectable suspension pack or other commercially-available needles to reduce the risk of blockage.

    Deltoid Injection

    The recommended needle size for administration of INVEGA TRINZA® into the deltoid muscle is determined by the patient's weight:

    • For patients weighing less than 90 kg, the 1-inch, 22 gauge thin wall needle is recommended.
    • For patients weighing 90 kg or more, the 1½-inch, 22 gauge thin wall needle is recommended.

    Administer into the center of the deltoid muscle. Deltoid injections should be alternated between the two deltoid muscles.

    Gluteal Injection

    Regardless of patient weight, the recommended needle size for administration of INVEGA TRINZA® into the gluteal muscle is the 1½-inch, 22 gauge thin wall needle. Administer into the upper-outer quadrant of the gluteal muscle. Gluteal injections should be alternated between the two gluteal muscles.

    Incomplete Administration

    To avoid an incomplete administration of INVEGA TRINZA®, ensure that the prefilled syringe is shaken vigorously for at least 15 seconds within 5 minutes prior to administration to ensure a homogeneous suspension and ensure the needle does not get clogged during injection [see Dosage and Administration (2.8)].

    However, in the event of an incompletely administered dose, do not re-inject the dose remaining in the syringe and do not administer another dose of INVEGA TRINZA®. Closely monitor and treat the patient with oral supplementation as clinically appropriate until the next scheduled 3-month injection of INVEGA TRINZA®.

    2.2 Schizophrenia

    Adults

    INVEGA TRINZA® is to be used only after INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension) has been established as adequate treatment for at least four months. In order to establish a consistent maintenance dose, it is recommended that the last two doses of INVEGA SUSTENNA® be the same dosage strength before starting INVEGA TRINZA®.

    Initiate INVEGA TRINZA® when the next 1-month paliperidone palmitate dose is scheduled with an INVEGA TRINZA® dose based on the previous 1-month injection dose, using the equivalent 3.5-fold higher dose as shown in Table 1. INVEGA TRINZA® may be administered up to 7 days before or after the monthly time point of the next scheduled paliperidone palmitate 1-month dose.

    Table 1. INVEGA TRINZA® Doses for Adult Patients Adequately Treated with INVEGA SUSTENNA®
    If the Last Dose of INVEGA SUSTENNA® is: Initiate INVEGA TRINZA® at the Following Dose:
    Conversion from the INVEGA SUSTENNA® 39 mg dose was not studied.
    78 mg 273 mg
    117 mg 410 mg
    156 mg 546 mg
    234 mg 819 mg

    Following the initial INVEGA TRINZA® dose, INVEGA TRINZA® should be administered every 3 months. If needed, dose adjustment can be made every 3 months in increments within the range of 273 mg to 819 mg based on individual patient tolerability and/or efficacy. Due to the long-acting nature of INVEGA TRINZA®, the patient's response to an adjusted dose may not be apparent for several months [see Clinical Pharmacology (12.3)].

    2.3 Missed Doses

    Dosing Window

    Missing doses of INVEGA TRINZA® should be avoided. If necessary, patients may be given the injection up to 2 weeks before or after the 3-month time point.

    Missed Dose 3½ Months to 4 Months Since Last Injection

    If more than 3½ months (up to but less than 4 months) have elapsed since the last injection of INVEGA TRINZA®, the previously administered INVEGA TRINZA® dose should be administered as soon as possible, then continue with the 3-month injections following this dose.

    Missed Dose 4 Months to 9 Months Since Last Injection

    If 4 months up to and including 9 months have elapsed since the last injection of INVEGA TRINZA®, do NOT administer the next dose of INVEGA TRINZA®. Instead, use the re-initiation regimen shown in Table 2.

    Table 2. Re-initiation Regimen After Missing 4 Months to 9 Months of INVEGA TRINZA®
    If the Last Dose of INVEGA TRINZA® was: Administer INVEGA SUSTENNA®, two doses one week apart (into deltoid muscle) Then administer INVEGA TRINZA® (into deltoid* or gluteal muscle)
    Day 1 Day 8 1 month after Day 8
    *
    See Instructions for Use for deltoid injection needle selection based on body weight.
    273 mg 78 mg 78 mg 273 mg
    410 mg 117 mg 117 mg 410 mg
    546 mg 156 mg 156 mg 546 mg
    819 mg 156 mg 156 mg 819 mg

    Missed Dose Longer than 9 Months Since Last Injection

    If more than 9 months have elapsed since the last injection of INVEGA TRINZA®, re-initiate treatment with the 1-month paliperidone palmitate extended-release injectable suspension as described in the prescribing information for that product. INVEGA TRINZA® can then be resumed after the patient has been adequately treated with the 1-month paliperidone palmitate extended-release injectable suspension for at least 4 months.

    2.4 Use with Risperidone or with Oral Paliperidone

    Since paliperidone is the major active metabolite of risperidone, caution should be exercised when INVEGA TRINZA® is coadministered with risperidone or oral paliperidone for extended periods of time. Safety data involving concomitant use of INVEGA TRINZA® with other antipsychotics is limited.

    2.5 Dosage Adjustment in Renal Impairment

    INVEGA TRINZA® has not been systematically studied in patients with renal impairment [see Clinical Pharmacology (12.3)]. For patients with mild renal impairment (creatinine clearance ≥ 50 mL/min to < 80 mL/min [Cockcroft-Gault Formula], adjust dosage and stabilize the patient using the 1-month paliperidone palmitate extended-release injectable suspension, then transition to INVEGA TRINZA® [see Table 1, Dosage and Administration (2.2)]. [See also Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]

    INVEGA TRINZA® is not recommended in patients with moderate or severe renal impairment (creatinine clearance < 50 mL/min) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].

    2.6 Switching from INVEGA TRINZA® to the 1-Month Paliperidone Palmitate Extended-Release Injectable Suspension

    For switching from INVEGA TRINZA® to INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension), the 1-month paliperidone palmitate extended-release injectable suspension should be started 3 months after the last INVEGA TRINZA® dose, using the equivalent 3.5-fold lower dose as shown in Table 3. The 1-month paliperidone palmitate extended-release injectable suspension should then continue, dosed at monthly intervals.

    Table 3. Conversion From INVEGA TRINZA® to INVEGA SUSTENNA®
    If the Last Dose of INVEGA TRINZA® is: Initiate* INVEGA SUSTENNA® 3 Months Later at the Following Dose:
    *
    The initiation dosing as described in the prescribing information for INVEGA SUSTENNA ® is not required.
    273 mg 78 mg
    410 mg 117 mg
    546 mg 156 mg
    819 mg 234 mg

    2.7 Switching from INVEGA TRINZA® to Oral Paliperidone Extended-Release Tablets

    For switching from INVEGA TRINZA® to oral paliperidone extended-release tablets, the daily dosing of the paliperidone extended-release tablets should be started 3 months after the last INVEGA TRINZA® dose and transitioned over the next several months following the last INVEGA TRINZA® dose as described in Table 4. Table 4 provides dose conversion regimens to allow patients previously stabilized on different doses of INVEGA TRINZA® to attain similar paliperidone exposure with once daily paliperidone extended-release tablets.

    Table 4. INVEGA TRINZA® Doses and Once-Daily Paliperidone Extended-Release Conversion Regimens Needed to Attain Similar Paliperidone Exposures
      Weeks Since Last INVEGA TRINZA® Dose
      3 months to 18 weeks Longer than 18 weeks to 24 weeks Longer than 24 weeks
    Last INVEGA TRINZA® Dose Doses of oral paliperidone extended-release tablets
    273 mg 3 mg 3 mg 3 mg
    410 mg 3 mg 3 mg 6 mg
    546 mg 3 mg 6 mg 9 mg
    819 mg 6 mg 9 mg 12 mg

    2.8 Instructions for Use

    Figure Administer every 3 months
    Figure Shake syringe vigorously for at least 15 seconds

    For intramuscular injection only. Do not administer by any other route.

    Important

     

    INVEGA TRINZA® should be administered by a healthcare professional as a single injection. DO NOT divide dose into multiple injections.

    INVEGA TRINZA® is intended for intramuscular use only. Inject slowly, deep into the muscle taking care to avoid injection into a blood vessel.

    Read complete instructions prior to use.

    Dosing

    This medication should be administered once every 3 months.

    Preparation

    Peel off tab label from the syringe and place in patient record.

    INVEGA TRINZA® requires longer and more vigorous shaking than INVEGA SUSTENNA® (1-month paliperidone palmitate extended-release injectable suspension). Shake the syringe vigorously, with the syringe tip pointing up, for at least 15 seconds within 5 minutes prior to administration (see Step 2).

    Thin Wall Safety Needle Selection

    Thin wall safety needles are designed to be used with INVEGA TRINZA®. Therefore, it is important to only use the needles provided in the INVEGA TRINZA® kit.

    Dose pack contents

        Prefilled Syringe   Thin Wall Safety Needles  
      Figure  

    1 Select needle

    Needle selection is determined by injection area and patient weight.

    If administering a Deltoid injection
    Figure
    If patient weighs:
    Less than 90 kg
    pink hub
    Figure
    If administering a Gluteal injection
    Figure
    If patient weighs:
    Less than 90 kg
    yellow hub
    Figure
    90 kg or more
    yellow hub
    Figure
    90 kg or more
    yellow hub
    Figure
    Figure

    2 Prepare for injection

    Figure

    Check suspension

    Figure

    After shaking the syringe for at least 15 seconds, check the liquid in the viewing window.

    The suspension should appear uniform and milky white in color.

    It is also normal to see small air bubbles.

    Open needle pouch and remove cap

    Figure

    First, open needle pouch by peeling the cover back half way. Place on a clean surface.

    Then, holding the syringe upright, twist and pull the rubber cap to remove.

    Grasp needle pouch

    Figure

    Fold back needle cover and plastic tray. Then, firmly grasp the needle sheath through the pouch, as shown.

    Attach needle

    Figure

    With your other hand, hold the syringe by the luer connection and attach it to the safety needle with a gentle clockwise twisting motion.

    Do not remove the pouch until the syringe and needle are securely attached.

    Remove needle sheath

    Figure
  • Tags: 责任编辑:admin
    】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
    分享到QQ空间
    分享到: 
    上一篇BONIVA® (ibandronate sodium.. 下一篇(paliperidone palmitate extende..

    相关栏目

    最新文章

    图片主题

    热门文章

    推荐文章

    相关文章

    广告位